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Abstract
OBJECTIVES: A very high percentage of patients submitted to coronary artery bypass grafting (CABG) develop symptomatic aortic
disease requiring surgery upon ageing. The surgical risk of the redo procedure is controversial. We describe our recent experience with
patients submitted to this surgery under such conditions.
METHODS: From July 1999 to July 2010, 51 patients (mean age, 70.3 ± 7.0 years, 86.3% male) submitted to CABG previously required
aortic valve surgery (AVS). The mean interval between the surgeries was 7.1 ± 3.9 years. Twenty-one patients (41.2%) had also undergone
AVS during the ﬁrst surgery [12 patients (57.7%) had valve replacement and 9 patients (42.8%) had valvuloplasty]. At presentation, 51.0%
were in New York Heart Association Class III/IV and the standard and logistic EuroSCOREs were 10.1 ± 2.5 and 20.9 ± 16.5%, respectively.
RESULTS: Aortic valve replacement was performed in 48 patients (94.1%). Two patients had undergone a surgery for the closure of a
peri-prosthetic leak and one patient a valvuloplasty. Thirteen patients (25.5%) needed to undergo additional cardiac procedures, includ-
ing root enlargement (three patients, 5.9%). Valve surgery was performed with non-dissection of the internal thoracic artery graft, when
patented, and antegrade cardioplegic arrest of other territories. Hospital and 30-day mortality rate was 2% (n = 1). The mean duration of
hospital stay was 13.0 ± 11.1 days. The most frequent complication was arrhythmias – in 25.5% of the patients, and mostly due to atrial
ﬁbrillation (19.6%). Permanent pacemaker for A-V block was required in 5.9% of the cases, stroke was documented in two cases (3.9%)
and early re-intervention was observed in two cases.
CONCLUSIONS: Redo AVS performed in patients submitted to CABG previously results in mortality and morbidity rates that are much
lower than what is expected, bringing clear beneﬁts to the patients.
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INTRODUCTION
A very high percentage of patients submitted to coronary artery
bypass grafting (CABG) with no or minimal aortic valve gradient
develop symptomatic aortic valvulopathy with hemodynamic
compromise upon ageing [1]. Other patients at risk are those
who had also undergone aortic valve surgery (AVS) during the
ﬁrst surgery and now present with recurrence of the disease.
These patients, with underlying ischaemic and valvular path-
ology, need to undergo a reoperation, which has been reported
to have a variable and controversial risk in the literature [2–9].
Many possible sources of risk have been identiﬁed, but the con-
sensus has been observed for damage to the patent internal
thoracic artery (ITA) grafts [3], haemorrhagic risk associated with
the dissection of the adhesions [9, 10] and the possible myocar-
dial injury associated with suboptimal myocardial protection
[10, 11]. No ideal surgical option or myocardial protection
method has been reported so far and all methods present risks.
However, despite an arduous search, no speciﬁc risk factor, other
than ageing, has been demonstrated to be associated with the
increasing risk of reoperation [7, 8]. International risk evaluation
scores, such as the EuroSCORE, estimate a substantially high mor-
tality rate for these patients, occasionally a prohibitive risk. This is
a situation that we have, however, not encountered in reality.
In this study, we aimed to evaluate the early outcomes in
patients operated at our institution in this type of surgical setting
during a recent 10-year period. We also aimed to characterize
the population and analyse the results, pointing out our
strengths and shortcomings.
MATERIALS AND METHODS
Study design, population and data collection
From July 1999 to July 2010, 3619 patients underwent an oper-
ation of the aortic valve at our institution. Of these, 51 patients
(1.4%) had a history of having undergone CABG previously and
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were analysed retrospectively. Patients who had to undergo
other concomitant procedures at primary or repeat operations
were not excluded from the analysis.
Data were collected prospectively using a standardized written
form by each involved surgeon, and validated and inputted into
a computerized database by a database director and preopera-
tive, operative and outcome variables were included.
Patient preoperative data
The preoperative characteristics of the patients are summarized
in Table 1. The population studied consisted of 51 patients, 44
males (86%) and 7 females (14%), with a mean age of 70.3 ± 7.0
years (range: 54–80). The time span between CABG and AVS was
7.1 ± 3.9 years (range: 0.3–15.3 years). Only one patient had
undergone the initial CABG elsewhere and one patient had
undergone AVS as the third cardiac procedure. The calculated
standard and logistic EuroSCOREs were 10.1 ± 2.5 and 20.9 ±
16.5%, respectively.
The mean number of grafts performed during the initial CABG
was 2.2 ± 0.8 (range: 1–3). The pedicled left internal thoracic
artery (LITA) was used in 44 patients (86.3%) to graft the left an-
terior descending artery (LAD) system. The right internal thoracic
artery (RITA) was used as a free graft to the circumﬂex (ﬁve
patients) or the right coronary (three patients) systems. Double
ITA grafts were used in eight patients (15.7%). At the time of the
second surgery, all the LITA grafts were patent and the overall
rate of patency of the RITA grafts to the circumﬂex system was
88% and that to the RCA system was 74%.
Twenty-one patients (41.2%) had undergone AVS during the
ﬁrst surgery [12 patients (57.7%) had prosthetic valve replace-
ment and 9 (42.8%) had valvuloplasty], concomitant with mitral
valvuloplasty in two patients. In the 12 patients who were sub-
mitted to prosthetic valve replacement in the ﬁrst surgery, a
mechanical valve was used in nine patients (75.0%) and a bio-
logical valve in three patients (25.0%). Six patients had undergone
other procedures associated with CABG: mitral valvuloplasty in
four patients, a pulmonary valve commissurotomy in one patient
and plasty of the left coronary ostium in one patient.
In the sub-group of 30 patients who had not undergone AVS
during the ﬁrst surgery, the indication for the redo procedure was
aortic stenosis in 18 patients (60%), with a mean gradient of 44 ±
12 mmHg and a mean valve area of 0.76 ± 0.29 cm2. Four patients
(13.3%) underwent an operation for aortic regurgitation, and eight
(26.7%) for mixed disease. The aetiology of the valve disease was
degenerative in 28 patients (93.3%) and rheumatic in two patients.
In the sub-group of 21 patients who had undergone AVS
during the ﬁrst surgery, the indication for operation was struc-
tural valve deterioration in 15 patients (71.4%) (six prosthetic and
nine repair), non-structural dysfunction in two patients (para-
valvular leak) and prosthetic valve endocarditis in four patients.
Technique of reoperation
The surgical approach that was followed was median resternot-
omy. Mediastinal and pericardial dissection was limited to the
ascending aorta and the right atrium. A patent left internal thor-
acic artery (LITA) graft to the anterior descending territory was
never dissected, controlled or clamped. Only a limited dissection
of other proximal graft anastomoses was performed, just enough
to avoid damage during aortic cross-clamping. All patients
underwent cardiopulmonary bypass with moderate systemic
hypothermia (25–28°). Cannulation was performed in the right
atrium and the ascending aorta of all the patients.
Decompression of the left ventricle was achieved by inserting a
vent through the right superior pulmonary vein. Antegrade cold
crystalloid cardioplegia was used in all the patients, injected in
the aortic root or directly in the native coronary and graft ostia if
aortic regurgitation was observed. If collateral backﬂow out of
the left main ostium (from the patent LITA) obscured the opera-
tive ﬁeld during AVS, pump ﬂows were temporarily turned down
for better visualization, or the ostium was occluded by placing a
cardioplegia cannula. Concomitant CABG was always performed
prior to AVS, in an empty beating or ﬁbrillating heart, a tech-
nique described in detail in a previous report by our group,
which had also been used in the original operation [12].
RESULTS
Operative data
The operative data are summarized in Table 2. Aortic valve re-
placement was performed in 48 patients (94.1%). Of these, 44
patients (86.3%) underwent replacement with a biological or
mechanical prosthesis, and in four patients (7.8%), an aortic
homograft was used. The type of prosthetic valve used was left
to the surgeon’s choice. In most cases, patients over the age of
70 years underwent aortic valve replacement with biological
prostheses (n = 24; 47.1%) and patients under the age of 70 years
Table 1: Preoperative patients’ dataa
Variable No. (%)b
Mean age (years) 70.3 ± 7.0
Male 44 (86)
Body mass index (kg/m2) 26.2 ± 2.1
Body surface area (cm2) 175.8 ± 14.8
Time interval between CABG and AVS (years) 7.1 ± 3.9
Hypertension 38 (74.5)
Dyslipidemia 41 (80.4)
Smoking history 19 (37.3)
Peripheral vascular disease 10 (19.6)
Cerebrovascular disease 6 (11.8)
Diabetes mellitus 11 (21.6)
Previous carotid endarterectomy 5 (9.8)
COPD 5 (9.8)
Renal failure 6 (11.8)
Previous myocardial infarction 11 (21.6)
NYHA Class ≥III 45 (51.0)
Permanent atrial fibrillation 7 (13.7)
Number of previous grafts 2.2 ± 0.8
LVEF (%) 53.6 ± 18.2
Non-elective surgery 2 (3.9)
PASP (mmHg) 46.4 ± 13.2
Additive EuroSCORE 10.1 ± 2.5
Logistic EuroSCORE 20.9 ± 16.5
AVS: aortic valve surgery; COPD: chronic obstructive pulmonary
disease; NYHA: New York Heart Association; LVEF: left ventricular
ejection fraction; PASP: pulmonary artery systolic pressure.
a The definition of some of these variables are presented in Appendix A.
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preferred mechanical prostheses (n = 20; 39.2%). In four patients
with prosthetic valve endocarditis, an aortic homograft was used.
Two patients were submitted to paravalvular leak closure and
one patient to aortic valvuloplasty.
The majority of the patients (74.5%) were submitted to AVS
alone, but 13 patients needed to undergo other procedures.
Redo CABG was performed in three patients. Enlargement of the
aortic annulus and root using a pericardial bovine patch was
performed in three patients (3.9%). One patient had undergone
ascending aorta replacement. Additional valvular procedures are
listed out in Table 2.
The mean cardiopulmonary bypass and aortic cross-clamping
times were 71.9 ± 25.9 and 42.3 ± 13.6 min, respectively.
One patient suffered injury of the LITA during sternal re-entry.
The injury was repaired on cardiopulmonary bypass and the
patient had an uneventful postoperative course.
Early outcome
The early results are summarized in Table 3 (and the deﬁnition
of some of the postoperative complications are summarized in
Appendix B.). The operative mortality rate was 2% (n = 1). One
patient died 56 days after the procedure due to multi-system
organ failure.
Six patients (11.8%) required inotropic support, but only one
patient (2.0%) for >24 h. Mechanical support (left ventricular as-
sistance) was used in one patient (2.0%). Eight patients (15.6%)
developed acute renal failure, but none required dialysis. One
patient (2.0%) had myocardial infarction (MI). It should be noted
that cardiac enzymes are routinely not checked postoperatively,
but only when hemodynamic instability, electrocardiograph
changes, or new regional wall-motion abnormalities indicated
that a clinically signiﬁcant event may have occurred. Hence, we
cannot exclude minor ischaemic events, not those that are clin-
ically signiﬁcant.
Supraventricular arrhythmias, mainly atrial ﬁbrillation, necessi-
tating medical and/or electrical treatment was observed in 10
patients (19.6%) and complete atrioventricular block needing
permanent pacemaker implantation was observed in three
patients (5.9%). One patient (2.0%) required re-exploration
because of haemorrhage. Two patients (3.9%) had a stroke and
one patient had respiratory failure (2.0%). A prolonged post-
operative duration of hospital stay (>14 days) was observed in
eight patients (15.6%). No cases of mediastinitis were observed.
The mean duration of hospital stay was 8 days (percentile 25—
7 days; percentile 75—10 days; mean, 13.0 ± 11.1 days) and, as a
rule, survivors were discharged to go home. No referral to
aftercare institutions was made.
DISCUSSION
Since the 1980s, many articles in the literature have been debat-
ing this subject. Our interest in this subject was awakened due to
the growing number of patients submitted to CABG previously
who were at a high risk of facing complications in a redo aortic
surgery, as predicted by the EuroSCORE risk evaluation. These
patients are now being presented as the ideal candidates for
transcatheter aortic valve implantation [13]. A literature search
showed that the scientiﬁc community does not have a consen-
sual answer to this question, as mortality and complication rates
vary substantially; hence, we decided to evaluate our centre’s ex-
perience in this setting. Other questions that should be raised
are: when should the aortic valve be operated during the ﬁrst
surgery; and which surgery should be done [14]?
The small number of cases involved in this series, representing
the experience of a single centre, is one of the shortcomings of
this study that can be pointed out. However, regarding the het-
erogeneous characteristics of the population, when compared
with those of given in other reports in the literature [4, 11, 15],
the sample of this study has the advantage of adding complexity
to the evaluation of the surgery, allowing a better understanding
of the real patient, as ischaemic and multi-valvular pathology
can occur at the same time.
This series, as patients were submitted to coronary catheter-
ization prior to reoperation, also allowed us to evaluate the
Table 3: Early outcome results
Variable No. (%)
Operative mortality 1 (2.0)
Inotropic support 6 (11.8)
Mechanical support 1 (2.0)
Myocardial infarction 1 (2.0)
Cerebrovascular accident 2 (3.9)
Acute renal failure 8 (15.6)
Respiratory failure 1 (2.0)
Reoperation for bleeding 1 (2.0)
Supraventricular arrhythmias 10 (20.0)
Prolonged postoperative duration of stay 8 (15.6)
Hospital stay (mean days) 13.0 ± 11.1






Aortic homograft 4 (7.8)
Paravalvular leak closure 2 (3.9)
Valvuloplasty 1 (2.0)
Size of prosthetic valve 22.6 ± 1.5 (range 20–25)
Type of surgery
Isolated AVS 38 (74.5)
AVS + CABG 3 (5.9)
AVS + aortic root enlargement 3 (5.9)
AVS +mitral valve replacement 2 (3.9)
AVS +mitral and tricuspid valvuloplasty 2 (3.9)
AVS +mitral valvuloplasty 1 (2.0)
AVS + tricuspid valvuloplasty 1 (2.0)
AVS + ascending aorta replacement 1 (2.0)
CPB time (min) 71.9 ± 25.9
With associated procedures 90.8 ± 39.8
Without associated procedures 65.4 ± 14.9
Aortic cross-clamping time (min) 42.3 ± 13.6
With associated procedures 52.9 ± 14.7
Without associated procedures 38.7 ± 11.3
Re-entry problems 1 (2.0)
AVS: aortic valve surgery; CABG: coronary artery bypass grafting; CPB:
cardiopulmonary bypass.
aFor continuous variables, data are shown as the mean ± the standard
deviation.
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patency of the grafts and thus infer about the patency of grafts
of our total population submitted to CABG. All grafts to the LAD
system (LITA) were patent, as were the 88% of grafts to the cir-
cumﬂex system and 74% of the grafts to the RCA system, at a
mean of 7 years after CABG, ﬁndings consistent with those
reported in the literature, including a signiﬁcantly better patency
of the arterial grafts, especially of the LITA to the LAD.
The success of this type of reoperation is demonstrated by the
low incidence of surgical complications (reduced incidence of
graft or heart lesions, pericardial effusion, reoperation or medias-
tinitis). One surgical aspect of the original procedure, not men-
tioned in the literature and a routine procedure implemented at
our centre, is the approximation of the pericardial fat at the end
of the CABG, allowing the leftward lateralization of the LITA graft
and hence reducing re-entry risk. This, associated with the
limited dissection of heart structures, can be responsible for the
low incidence of graft lesions in the dissection. Neither femoral
nor axillary artery cannulation was used at the beginning of the
surgery or was needed later during the reoperation, indicating
that this is a safe procedure. No preoperative co-morbidity was
associated with the higher risk of complications [16].
The type of aortic valve to be implanted was decided by the
surgeon in accordance with the patient’s preference, age and life
expectancy. A mechanical valve is generally implanted in
patients up to the age of 70 years, unless the patient is of a dif-
ferent opinion. In our centre, patients over 75 years of age
always undergo aortic valve replacement with a biological pros-
thesis, but a signiﬁcant number of patients between 70 and 75
years of age, with a long life expectancy, opted for mechanical
prostheses, as we believe this to be a better alternative. In
patients with active infection involving the annulus uniformly, an
aortic homograft procedure was used as a mini-root one [17].
Our strategy for myocardial protection excludes clamping of the
LITA in addition to antegrade cardioplegia to the remaining coron-
ary territories. This could potentially lead to irregular myocardial
protection and possible ischaemic complications, which, however,
were not observed. Similarly, Smith et al. [18], using a similar tech-
nique, failed to demonstrate any increase in the mortality rates,
while Park et al. [19], from the Mayo Clinic, found increased mor-
tality rates in cases where clamping of the ITA was pursued.
Beyond a low operative mortality rate, in this study the inci-
dence of perioperative MI was 2.0%. Because we did not
measure the biomarkers of myocardial necrosis, the rate of this
event may be, by some standards, low. In an important earlier
analysis of this ‘non-ITA dissection’ approach carried out by
Byrne et al. [11], the incidence of perioperative MI was 9% (de-
ﬁning MI as new Q-wave in the electrocardiogram, creatine
kinase-MB (CK-MB) ≤50 IU/l, and CK-MB/CK ratio >5% or new
wall motion abnormality on echocardiography). In the more
recent studies carried out by Smith et al. [18] and Park et al. [19],
however, the reported incidence of MI was much lower (0.9 and
0%, respectively). In these studies, MI was deﬁned according to
the STS database criteria.
Our results are similar to those obtained using other tech-
niques to control the LITA ﬂow, such as supraclavicular control
[20], endovascular control [21], retrograde cardioplegia [22] or
beating heart [23]. Furthermore, the low mortality rate, observed
with regard to our surgical procedure, can be seen as a demon-
stration of safety. Somehow, a balance between continuous per-
fusion of the LAD territory and cardioplegic protection of the
remaining myocardium is achieved with this method. Two series
recently reported by Redlich et al. and Gazzoli et al. [24, 25], not
known to us at the beginning of our experience and at the time
of the presentation of this paper at the Annual Meeting, where a
similar technique was used, conﬁrmed these ﬁndings.
We believe that the short ECC and cross-clamping times also
contributed to good myocardial preservation. We have to
concede, however, that the retrospective nature and the short
follow-up period are important imitations of our study.
CONCLUSION
Although performing AVS after CABG is a challenging task, we
have conﬁrmed that it is feasible, resulting in mortality and com-
plication rates that are lower than what is expected from the risk
score systems that are available. We believe that this surgical ap-
proach based on a no-touch handling of the patent LITA graft
and performing the procedure expeditiously is the mainstay of
the success.
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APPENDIX A.
Table A1: Deﬁnition of preoperative variables
Hypertension Blood pressure exceeding 140/90 mmHg,
a history of high blood pressure or the
need of antihypertensive medications
Renal failure Creatinine >2.0 mg/dl and no dialysis
dependence




Patient requires pharmacologic therapy for
the treatment of chronic pulmonary
compromise or patient has a FEV1
level <75% of the predicted value
Peripheral vascular
disease
Claudication either with exertion or at
rest; amputation for arterial
insufficiency; aorto-iliac occlusive
disease reconstruction; peripheral
vascular bypass surgery, angioplasty or
stent; documented abdominal aorta
aneurism, repair or stent or
non-invasive carotid test with >75%
occlusion
Cerebrovascular disease Unresponsive coma >24 h, cerebrovascular
accident (CVA), RIND or TIA
Non-elective surgery Urgent or emergent surgery
FEV1: forced expiratory volume in the first second; RIND: reversible
ischaemic neurologic deficit; TIA: transient ischemic attack.
APPENDIX B.
Table B1: Deﬁnition of postoperative complications
Operative mortality Death from all causes, during the same
hospitalization stay, regardless of the
time or within 30 days of surgery
CVA Global or focal neurological deficit lasting
<24 h (transient ischaemic attack) or
>24 h (reversible ischaemic neurologic
deficit; stroke)
Mediastinitis At least one of the following: (1) an
organism isolated from culture of
mediastinal tissue or fluid; (2) evidence
of mediastinitis observed during
operation; (3) one of the following
conditions: chest pain, sternal instability
or fever (>38°C), in combination with
either purulent discharge from the
mediastinum or an organism isolated
from blood culture or culture of
mediastinal drainage
Myocardial infarction New Q-wave in the electrocardiogram,
creatine kinase-MB (CK-MB) ≥50 IU/l,
and CK-MB/CK ratio >10%
Inotropic support Use of one or more inotropic drugs, for
any length of time
Mechanical support Use of intra-aortic balloon pumping or
ventricular assistance
Acute renal failure Postoperative creatinine serum level of
≥2.1 mg/dl plus an increase in the serum
creatinine level of ≥0.9 mg/dl from
preoperative to maximum postoperative
values in patients who had no significant
pre-existing renal disease (creatinine
≤2.0 mg/dl and no dialysis dependence)
Reoperation for bleeding Bleeding or cardiac tamponade that




Duration of stay >14 days (alive or dead)
Respiratory failure Postoperative ventilator support for >48 h
or tracheostomy or both
APPENDIX. CONFERENCE DISCUSSION
Dr D. Pagano (Birmingham, UK): There are two main messages, to my mind,
in your paper. It is that this is very difﬁcult and complicated surgery, which
your team does extremely well, and also that EuroSCORE is absolutely useless
in predicting outcomes in these patients.
I have a question. This is a single-centre series with excellent results. How
do you deal nowadays, in 2011, with patients that come to surgery for
primary myocardial revascularization who have some degree of aortic valve
stenosis? In which ones do you replace the valve, in which ones not, and
what do you do afterwards for follow-up?
Dr Paupério: We measure the gradient intraoperatively, and if it is higher
than 20 mm, we substitute the valve.
Dr Pagano: That is mean gradient?
Dr Paupério: Peak to peak.
Dr Pagano: Sorry?
Dr Paupério: We insert a needle in the left ventricle and a needle in the
aorta, and if the difference is higher than 20 mm, we perform aortic valve
substitution. We have to have a suspicion index before surgery by echo. If we
have a gradient near 20 mmHg, we perform this manoeuvre to conﬁrm that
the gradient is signiﬁcant, and then we substitute the valve.
Dr Pagano: I am a little bit at a loss here, because it is widely recognized
that the best way to assess the aortic valve is by transthoracic and transoeso-
phageal echocardiogram. So I am not quite sure how your decision-making is
done intraoperatively on a beating heart with a needle through the aorta and
through the left ventricular outﬂow tract. I am not quite sure. Can you
expand a little bit more?
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Dr Paupério: If we have a degree of suspicion, we have to be sure that this
gradient is signiﬁcant and we conﬁrm it by using peak to peak gradient. We
know that the patient is relaxed and that the gradient can be lower, but we also
know that if we have to intervene in this valve later, we have a low mortality. So
probably we can postpone this surgery to a later opportunity, because we know
that by replacing the valve earlier, we have the risks associated with anticoagu-
lation and, if the valve is a biological valve, with degeneration. Therefore if the
gradient isn’t signiﬁcant, we prefer to postpone or even not to intervene.
Dr Pagano: Are there any other parameters you use apart from the gradient
to decide in which patients you are going to replace the valve prophylactically?
Dr Paupério: Sorry?
Dr Pagano: Are there any other variables that you consider when you
make the decision whether to replace the valve prophylactically, or do you
ever replace the valve prophylactically below a 20 mmHg gradient?
Dr Paupério: When the gradient is lower than 20, we usually don’t replace
the valve. I don’t have that data, but I don’t think we usually perform aortic
valve surgery in such patients. That is not the common practice in our centre.
Dr Pagano: I have no further questions.
Dr M. Antunes (Coimbra, Portugal): I am the senior author of this paper
and this series. Just to clarify Dr Pagano’s question and Dr Paupério’s answer,
this series comes about because we were not as aggressive before with mild
to moderate degrees of aortic valve disease. Subsequent to these results and
in the last couple of years, of course, we have been more aggressive, as is
everybody else, in operating prophylactically on the aortic valve. Basically the
decision is made preoperatively, not intraoperatively, usually on a mean
echocardiographic gradient of 20, 25, 30 mmHg, which otherwise would not
be an indication for surgery, but it is an indication concomitant with grafting
the coronaries. That is our current policy.
We do have this old habit of placing a needle in the left ventricle in the
operating room, but that just serves, as Dr Paupério mentioned, to conﬁrm
that we indeed have a gradient. We also perform intraoperative transoeso-
phageal echo in these patients just to conﬁrm that the valve is sclerotic and
needs replacement.
Dr B. Podesser (St. Pölten, Austria): Just one comment. You said that the
mean age of your population is 70 years but still you have more than 40% of
mechanical valves. Have you seen a change in your policy over the period of
your series? Do you use biological valves more frequently than mechanical
valves today, because I think 45 to 48% mechanical is a pretty high percentage.
Dr Paupério: Usually when the patient is over 70 years, we use a biological
valve and under 70 years we use a mechanical valve. But there is a group of
patients between 70 and 75 years in whom the surgeon can sometimes use a
mechanical valve if the patient has few co-morbidities and potentially has a
higher life expectancy.
Dr Podesser: Well, the results of the biological valves are very good at the
age of 65, so I think you maybe should reconsider this, because you don’t
have to put your patients on warfarin.
Dr S. Siminelakis (Ioannina, Greece): About myocardial protection, when
the LIMA is open, how do you protect the myocardium?
Dr Paupério: We never clamp the LIMA when we have a patent LIMA. In
44 patients that was the scenario. We administer cardioplegia directly in the
coronary ostia and in the grafts. We think that we can obtain myocardial pro-
tection with cardioplegia, and the oxygenated blood supplied by the LIMA
graft. And we perform, as could be seen, very quick surgery with short cross-
clamp times.
Dr Siminelakis: So you use cold crystalloid cardioplegia and you don’t
clamp?
Dr Paupério: We never clamp the LIMA.
Dr Siminelakis: But the heart is warming then, in three minutes it will be
warm again.
Dr Paupério: Yes, but we believe that this kind of myocardial protection is
sufﬁcient. And we can see from the results that we don’t have many myocar-
dial infarctions. The mean left ventricular ejection fraction was the same
before and after the procedure.
Dr Siminelakis: It seems strange to me.
Dr T. Folliguet (Paris, France): You are cooling the temperature of the
body?
Dr Paupério: Yes, and we have mild hypothermia.
Dr Siminelakis: You said 28.
Dr Paupério: 25 to 28.
Dr Siminelakis: 25 is different than 28.
Dr Paupério: It depends on the procedure, because we have surgeries that
include other concomitant procedures.
Dr Folliguet: Professor Antunes.
Dr Antunes: That is what he explained, but the main key message of this
technique is that over time with our experience we found that we somehow,
although it may be difﬁcult to explain, we found an equilibrium between
giving cardioplegia more repetitively in the coronary ostia and having the
area that is supplied by the internal mammary artery undisturbed. We found
that our results have improved tremendously as compared to the time when
we spent a lot of effort mobilizing and clamping the internal mammary
artery.
By the way, there is only one technical problem, which is that, often, if it is
a good internal mammary artery and a good LAD, you have a lot of ﬂow
back through the left coronary ostium. We just place a cardioplegic cannula
just to occlude it, not to give cardioplegia. It makes the operation so much
simpler.
Dr Siminelakis: Retrograde cardioplegia?
Dr Antunes: Well, we don’t use it in our experience for any other cases, so
we have not used it in this series, but I concede that it possibly could be a so-
lution as well.
My message of this series is exactly this: spending a lot of time controlling
the patent LIMA not only gives rise to possible accidents, but also does not
appear to have any favourable outcome as compared to not touching the
LIMA.
Dr Siminelakis: That is very important. And the temperature goes down to
25?
Dr Antunes: We usually go to 30 degrees, somewhere around that.
Dr Folliguet: I think we can continue discussion outside, if you want,
because we really have to ﬁnish. But I agree, we do the same; we don’t
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